# Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

> **NCT02823951** · — · COMPLETED · sponsor: **IMS HEALTH GmbH & Co. OHG** · enrollment: 479 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** Rebif
- **DRUG:** Tecfidera

## Key facts

- **NCT ID:** NCT02823951
- **Lead sponsor:** IMS HEALTH GmbH & Co. OHG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2017-04
- **Final completion:** 2018-02
- **Target enrollment:** 479 (ACTUAL)
- **Last updated:** 2018-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02823951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02823951, "Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02823951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*